{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:30:46Z","timestamp":1793640646766,"version":"4.5.1"},"reference-count":27,"publisher":null,"issue":"2","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/cardio.elpub.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    \u00a0 \u00a0Heart failure (HF) patients with type 2 diabetes mellitus (T2DM) are at high risk of hospital readmission due to cardiovascular events. Glycemic control may play a key role in reducing this risk, but the optimal glycemic control threshold for preventing readmissions remains unclear.\n                    <jats:italic>Material and methods<\/jats:italic>\n                    \u00a0 \u00a0 This single-center, retrospective cohort study included 160 adult patients with HF and type 2 diabetes mellitus (T2DM). Patients were classified into two groups based on HbA1c measured 3 months after discharge: poor glycemic control (HbA1c \u2265 7.0\u200a%) and good glycemic control (HbA1c &lt; 7.0\u200a%). Data were collected from electronic medical records, and cardiovascular event readmissions were tracked over a one-year follow-up period. Kaplan\u2013Meier event-free survival (EFS) analysis and Cox regression models were used to examine the relationship between the three-month HbA1c and cardiovascular event readmission. A Fine\u2013Gray competing-risk model was additionally applied to provide a more robust estimate of the cumulative incidence of cardiovascular readmission.\n                    <jats:italic>Results \u00a0 \u00a0<\/jats:italic>\n                    \u00a0 \u00a0 Among the 160 patients, 56 (35\u200a%) were readmitted due to cardiovascular events, including HF exacerbation (39.3\u200a%), myocardial infarction (25.0\u200a%), arrhythmias (14.3\u200a%), and coronary artery disease (8.9\u200a%). Their median EFS time was 121 days. The readmission rate was significantly higher in patients with poor glycemic control (HbA1c \u22657.0\u200a%), with 58.8\u200a% of the patients being readmitted compared to 17.4\u200a% in the group with good glycemic control (HbA1c &lt;7.0\u200a%, p&lt;0.001). Kaplan\u2013Meier EFS analysis confirmed a significantly shorter EFS in patients with poor glycemic control. Cox regression analysis identified the three-month HbA1c value as an independent predictor of cardiovascular event readmission (HR=3.41, 95\u200a% CI 2.15\u20135.29, p&lt;0.001), which was consistent with the Fine\u2013Gray competing-risk analysis (sub-distribution HR = 3.12, 95\u200a% CI 1.95\u20134.98, p&lt;0.001).\n                    <jats:italic>Conclusion \u00a0<\/jats:italic>\n                    \u00a0Early glycemic control, particularly the three-month HbA1c value, is a strong predictor of cardiovascular event readmission in HF patients with DM. Optimizing glycemic control within the first three months post-discharge may significantly reduce readmission risk and improve clinical outcomes.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2026.2.n2913","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:33:26Z","timestamp":1775129606000},"page":"52-60","source":"Crossref","is-referenced-by-count":0,"title":["Early Post-discharge Glycemic Control and Cardiovascular Event Readmission in Patients With Heart Failure and Type 2 Diabetes: A Single-center Retrospective Cohort Study"],"prefix":"10.68900","volume":"66","author":[{"given":"Hong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xionger","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Keshvani N, Subramanian V, Wrobel CA, Solomon N, Alhanti B, Greene SJ et al. Patterns of Referral and Postdischarge Utilization of Cardiac Rehabilitation Among Patients Hospitalized With Heart Failure: An Analysis From the GWTG-HF Registry. Circulation: Heart Failure. 2023;16(8):e010144. DOI: 10.1161\/CIRCHEARTFAIL-URE.122.010144","DOI":"10.1161\/CIRCHEARTFAILURE.122.010144"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2023;81(18):1810\u201334. DOI: 10.1016\/j.jacc.2023.01.049","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M et al. Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2023;25(6):776\u201391. DOI: 10.1002\/ejhf.2874","DOI":"10.1002\/ejhf.2874"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Xu R, Wu M, Wang Y, Li C, Zeng L, Wang Y et al. Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-\u03b2-SMAD2\/3 pathway. Molecular Medicine. 2023;29(1):59. DOI: 10.1186\/s10020-023-00630-9","DOI":"10.1186\/s10020-023-00630-9"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Buse JB. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. The American Journal of Cardiology. 2007;99(12):S21\u201333. DOI: 10.1016\/j.amjcard.2007.03.003","DOI":"10.1016\/j.amjcard.2007.03.003"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022;145(6):437\u201347. DOI: 10.1161\/CIRCULATIONAHA.121.057983","DOI":"10.1161\/CIRCULATIONAHA.121.057983"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sinha B, Ghosal S. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials. Diabetes Therapy. 2021;12(6):1661\u201376. DOI: 10.1007\/s13300-021-01062-6","DOI":"10.1007\/s13300-021-01062-6"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S et al. Haemoglobin A1c (HbA1C) in Non-diabetic and Diabetic Vascular Patients. Is HbA1C an Independent Risk Factor and Predictor of Adverse Outcome? European Journal of Vascular and Endovascular Surgery. 2006;32(2):188\u201397. DOI: 10.1016\/j.ejvs.2006.01.011","DOI":"10.1016\/j.ejvs.2006.01.011"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. 2020;26(5):429\u201337. DOI: 10.1016\/j.cardfail.2020.02.001","DOI":"10.1016\/j.cardfail.2020.02.001"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Li R, Shan Y, Gao L, Wang X, Wang X, Wang F. The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K\/Akt1 and AMPKa Signaling. Frontiers in Pharmacology. 2019;10:537. DOI: 10.3389\/fphar.2019.00537","DOI":"10.3389\/fphar.2019.00537"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Cai J, Huang D, Abdul Kadir HB, Huang Z, Ng LC, Ang A et al. Hospital Readmissions for Fluid Overload among Individuals with Diabetes and Diabetic Kidney Disease: Risk Factors and Multivariable Prediction Models. Nephron. 2024;148(8):523\u201335. DOI: 10.1159\/000538036","DOI":"10.1159\/000538036"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008;61(4):344\u20139. DOI: 10.1016\/j.jclinepi.2007.11.008","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circulation Research. 2021;128(10):1421\u201334. DOI: 10.1161\/CIRCRESAHA.121.318172","DOI":"10.1161\/CIRCRESAHA.121.318172"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology. 2021;9(10):653\u201362. DOI: 10.1016\/S2213-8587(21)00203-5","DOI":"10.1016\/S2213-8587(21)00203-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Umpierrez GE, Castro-Revoredo I, Moazzami B, Nayberg I, Zabala Z, Galindo RJ et al. Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge. Endocrine Practice. 2025;31(3):286\u201391. DOI: 10.1016\/j.eprac.2024.11.018","DOI":"10.1016\/j.eprac.2024.11.018"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Pappada SM, Woodling K, Owais MH, Zink EM, Dahbour L, Tripathi RS et al. Continuous glucose monitoring identifies relationship between optimized glycemic control and post-discharge acute care facility needs. BMC Research Notes. 2018;11(1):533. DOI: 10.1186\/s13104-018-3656-3","DOI":"10.1186\/s13104-018-3656-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kim H, Jung DY, Lee S-H, Cho J-H, Yim HW, Kim H-S. Long-Term Risk of Cardiovascular Disease Among Type 2 Diabetes Patients According to Average and Visit-to-Visit Variations of HbA1c Levels During the First 3 Years of Diabetes Diagnosis. Journal of Korean Medical Science. 2023;38(4):e24. DOI: 10.3346\/jkms.2023.38.e24","DOI":"10.3346\/jkms.2023.38.e24"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Jiao X, Zhang Q, Peng P, Shen Y. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease. Diabetology & Metabolic Syndrome. 2023;15(1):50. DOI: 10.1186\/s13098023-01015-y","DOI":"10.1186\/s13098-023-01015-y"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights. 2016;11:95\u2013104. DOI: 10.4137\/BMI.S38440","DOI":"10.4137\/BMI.S38440"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zakir M, Ahuja N, Surksha MA, Sachdev R, Kalariya Y, Nasir M et al. Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways. Cureus. 2023;15(9):e45835. DOI: 10.7759\/cureus.45835","DOI":"10.7759\/cureus.45835"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Elendu C, Amaechi DC, Elendu TC, Ashna M, Ross-Comptis J, Ansong SO et al. Heart failure and diabetes: Understanding the bidirectional relationship. Medicine (Baltimore). 2023;102(37):e34906. DOI: 10.1097\/MD.0000000000034906","DOI":"10.1097\/MD.0000000000034906"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology. 2018;34(5):575\u201384. DOI: 10.1016\/j.cjca.2017.12.005","DOI":"10.1016\/j.cjca.2017.12.005"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Fiorentino T, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases. Current Pharmaceutical Design. 2013;19(32):5695\u2013703. DOI: 10.2174\/1381612811319320005","DOI":"10.2174\/1381612811319320005"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wu Z, Liu J, Zhang D, Kang K, Zuo X, Xu Q et al. Expert consensus on the glycemic management of critically ill patients. Journal of Intensive Medicine. 2022;2(3):131\u201345. DOI: 10.1016\/j.jointm.2022.06.001","DOI":"10.1016\/j.jointm.2022.06.001"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Adamo M, Anker MS, Von Haehling S, Coats AJS, Metra M. Heart Failure in the Last Year: Progress and Perspective. ESC Heart Failure. 2020;7(6):3505\u201330. DOI: 10.1002\/ehf2.13124","DOI":"10.1002\/ehf2.13124"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX et al. Mitochondrial Energetics in the Heart in Obesity-Related Diabetes. Diabetes. 2007;56(10):2457\u201366. DOI: 10.2337\/db07-0481","DOI":"10.2337\/db07-0481"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. The Lancet Global Health. 2018;6(11):e1196\u2013252. DOI: 10.1016\/S2214-109X(18)30386-3","DOI":"10.1016\/S2214-109X(18)30386-3"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/viewFile\/2913\/1980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:12Z","timestamp":1793639772000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2026.2.n2913","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}